Macías A, Pascual M R, Pérez R, Lage A
Neoplasma. 1983;30(5):593-601.
We have found no correlation between progesterone receptor PgR content in human breast tumors and clinical factors associated with the presence of estrogen receptor (ER, age, menopausal status, parity, age at first childbirth, menarche), in spite of the positive correlation between both receptors. Moreover, the association between clinical factors and the percentage of ER(-) PgR(-) tumors were identical to those of ER(-) tumors, but the association between clinical factors and the percentage of ER(+) PgR(-) tumors were inverse to those of ER(-) tumors. That implies that clinical factors associated with the presence of estrogen receptor can not distinguish ER(+) PgR(+) and ER(+) PgR(-) tumors. The stage of the disease is the most important clinical feature in breast cancer patients. In our series the pattern of hormone-receptor was different between Stages I/II and Stage III patients, while the percentage of PgR(+) tumors was constant, a decrease in ER(+) tumors occurred in Stage III patients. In addition similar percentages of ER(+) PgR(+) were found in both groups, but an increase in ER(-) PgR(-) tumors and a decrease in ER(+) PgR(-) tumors occurred in the Stage III patients. Altogether these results suggest that primary loss of progesterone receptors and primary loss of estrogen receptors could be related to different pathogenic mechanisms.
我们发现，尽管人乳腺肿瘤中的孕激素受体（PgR）含量与雌激素受体（ER）存在相关的临床因素（年龄、绝经状态、产次、初产年龄、月经初潮）之间存在正相关，但两者之间并无关联。此外，临床因素与ER（-）PgR（-）肿瘤百分比之间的关联与ER（-）肿瘤相同，但临床因素与ER（+）PgR（-）肿瘤百分比之间的关联与ER（-）肿瘤相反。这意味着与雌激素受体存在相关的临床因素无法区分ER（+）PgR（+）和ER（+）PgR（-）肿瘤。疾病分期是乳腺癌患者最重要的临床特征。在我们的系列研究中，I/II期和III期患者的激素受体模式不同，虽然PgR（+）肿瘤的百分比保持不变，但III期患者中ER（+）肿瘤的百分比有所下降。此外，两组中ER（+）PgR（+）的百分比相似，但III期患者中ER（-）PgR（-）肿瘤增加，ER（+）PgR（-）肿瘤减少。总之，这些结果表明，孕激素受体的原发性缺失和雌激素受体的原发性缺失可能与不同的致病机制有关。
